Bal Pharma Limited today announced the financial results reporting significant growth both in sales as well as profits for its first fiscal quarter ended June 30, 2008

Highlights of the Results:
* Turnover for the quarter ended 30th June 2008 is Rs. 28.42 crores, which is higher by 42.46% over the corresponding year figures of Rs. 19.95 crores.
* Profit before tax (PBT) was Rs. 2.55 crores, compared to Rs. 1.34 crores of previous year, a rise by 90.3% crores and PAT has also gone up by 60%.
Commenting on the results Mr. Shailesh Siroya, Managing Director, Bal Pharma Limited said, “Our results for this quarter confirm that we are on the right track and fast approaching our vision of being a 1000 crore group in the near future.”

In the first three months the company has offered 7 products to the Indian market and plans to touch 10 crore business from the new range. The new products entered the Indian Pharmaceuticals market are Aziwin AX, Glyvog, Telong, Telong H, Rabifix 20, Rabifix D & Balpro Syrup. The company has also expanded its work force across the country with special attention in Uttar Pradesh (India’s largest pharma market) to Andhra Pradesh and West Bengal. It has also forayed into foreign shores and has been successful in making an impact. The company would be entering 15 new countries within next financial year.

Tags: calls, daytrading, free calls, intraday, tips

Similar Posts:

• Indiabulls Fin posts 74.4% growth in total revenues
• Wipro records 43% growth in total revenue (US GAAP)
• GSK Pharma profits up by 19%
• SDBL’s total income up by 153% to Rs 29 crore
• WIL posts revenue up by 24.7% to Rs 156.51cr